Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females

Bibliography

• Haylen BT, De Ridder D, Freeman RM, International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
   PubMed Web of Science ®Google Scholar
• Cardozo L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J 2011;5:139-42
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90
   PubMed Web of Science ®Google Scholar
• Mukerji G, Yiangou Y, Grogono J, Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006;176:367-73
   PubMed Web of Science ®Google Scholar
• Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 2009;83:259-69
   PubMed Web of Science ®Google Scholar
• Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999;64:419-28
   PubMed Web of Science ®Google Scholar
• Uchiyama T, Chess-Williams R. Muscarinic receptor subtypes of the bladder and gastrointestinal tract. J Smooth Muscle Res 2004;40:237-47
   PubMedGoogle Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011;59:377-86
   PubMed Web of Science ®Google Scholar
• Yusup A, Akino H, Miwa Y, Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder. Eur J Pharmacol 2007;577:143-9
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012; doi: 10.1111/j.1464-410X.2012.11023.x
   PubMed Web of Science ®Google Scholar
• Shaya FT, Blume S, Gu A, Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11:121-9
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009;181:1764-72
   PubMed Web of Science ®Google Scholar
• Baldwin CM, Keating GM. Transdermal oxybutynin. Drugs 2009;69:327-37
   PubMed Web of Science ®Google Scholar
• Alabaster VA. Discovery & development of selective M3 antagonists for clinical use. Life Sci 1997;60:1053-60
   PubMed Web of Science ®Google Scholar
• Beaumont KC, Cussans NJ, Nichols DJ, Smith DA. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 1998;28:63-75
   PubMed Web of Science ®Google Scholar
• Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006;45:325-50
   PubMed Web of Science ®Google Scholar
• Fuhr U, Staib AH, Harder S, Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol 1994;38:83-6
   PubMed Web of Science ®Google Scholar
• Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003;56:639-52
   PubMed Web of Science ®Google Scholar
• Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009;47:570-8
   PubMed Web of Science ®Google Scholar
• Zinner N. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother 2007;8:511-23
   PubMed Web of Science ®Google Scholar
• Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787-96
   PubMed Web of Science ®Google Scholar
• Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008;46:556-63
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008;101:1036-42
   PubMed Web of Science ®Google Scholar
• Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 2009;139:146-51
   PubMed Web of Science ®Google Scholar
• McKeage K, Keating GM. Fesoterodine. Drugs 2009;69:731-8
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Hallen B, Larsson G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129-36
   PubMed Web of Science ®Google Scholar
• Malhotra BK, Glue P, Sweeney K, Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
   PubMed Web of Science ®Google Scholar
• Malhotra B, Wood N, Guan Z, Pharmacokinetic profile of fesoterodine, a novel antimuscarinic treatment for overactive bladder. Br J Clin Pharmacol 2008;65:999-1000
   Web of Science ®Google Scholar
• Malhotra B, Gandelman K, Sachse R, The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009;16:4481-9
   PubMed Web of Science ®Google Scholar
• Malhotra B, Dickins M, Alvey C, Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol 2011;72:263-9
   PubMed Web of Science ®Google Scholar
• Kanayama N, Kanari C, Masuda Y, Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica 2007;37:139-54
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Segawa M, Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007;57:92-100
   PubMed Web of Science ®Google Scholar
• Murakami S, Yoshida M, Iwashita H, Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 2003;71:290-8
   PubMed Web of Science ®Google Scholar
• Ohno T, Nakade S, Nakayama K, Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol 2008;65:197-202
   PubMed Web of Science ®Google Scholar
• Shimada H, Yafune A, Shibata H, Phase I clinical study of imidafenacin (KRP-197/ONO-8025): single-dose safety and pharmacokinetics of imidafenacin in healthy subjects. J Clin Ther Med 2007;23:233-48
   Google Scholar
• Shimada H, Hasunuma T, Hirahara Y, Ishikawa N. Pharmacokinetic study of imidafenacin (KRP-197/ONO-8025): pharmacokinetics of single oral administration of imidafenacin tablet 0.1 mg and food-effect on its oral absorption in healthy male volunteers. J Clin Ther Med 2007;23:273-85
   Google Scholar
• Ohmori S, Miura M, Toriumi C, Absorption, metabolism and excretion of [14C] imidafenacin, a new compound for treatment of overactive bladder, following oral administration to healthy male subjects. Drug Metab Dispos 2007;35:1624-33
   PubMed Web of Science ®Google Scholar
• Shimada H, Shibata H, Hirahara Y, Masuda Y. Investigation on safety and pharmacokinetic profile of imidafenacin (KRP-197/ONO-8025) after single administration in the eldery. J Clin Ther Med 2007;23:263-72
   Google Scholar
• Ohno T, Nakayama K, Nakade S, Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects. J Clin Pharmacol 2008;48:330-4
   Google Scholar
• Nakade S, Ohno T, Nakayama K, No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. Drug Metab Pharmacokinet 2008;23:95-100
   PubMed Web of Science ®Google Scholar
• Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
   PubMed Web of Science ®Google Scholar
• Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N- desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997;157:1093-7
   PubMed Web of Science ®Google Scholar
• Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001;52:409-17
   PubMed Web of Science ®Google Scholar
• Douchamps J, Derenne F, Stockis A, The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-20
   PubMed Web of Science ®Google Scholar
• Caldwell J, Marsh MV. Metabolism of drugs by the gastrointestinal tracts. In: George CF, Shand DG, editors. Clinical pharmacology and therapeutics 1: presystemic drug elimination. Butterworth Scientific®; London: 1982. p. 29-42
   Google Scholar
• Paine MF, Khaighi M, Fisher JM, Characterization of interintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62
   PubMed Web of Science ®Google Scholar
• Hughes KM, Lang JCT, Lazare R, Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69
   PubMed Web of Science ®Google Scholar
• Alberti I, Grenier A, Kraus H, Carrara DN. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2005;2:935-50
   PubMed Web of Science ®Google Scholar
• Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000;16:149-55
   PubMed Web of Science ®Google Scholar
• Davila GW. Transdermal oxybutynin: a new treatment for overactive bladder. Expert Opin Pharmacother 2003;4:2315-24
   PubMed Web of Science ®Google Scholar
• Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009;10:3103-11
   PubMed Web of Science ®Google Scholar
• Lukkari E, Hakonen T, Neuvonen PJ. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Eur J Clin Pharmacol 1998;53:351-4
   PubMedGoogle Scholar
• Hughes KM, Lang JC, Lazare R, Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69
   PubMed Web of Science ®Google Scholar
• Uchida S, Kurosawa S, Fujino Oki T, Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci 2007;80:2454-60
   PubMed Web of Science ®Google Scholar
• Wuest M, Weiss A, Waelbroeck M, Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 2006;374:87-97
   PubMedGoogle Scholar
• Hüller G, Haustein KO, Scheithauer S. Studies on the metabolic pattern of propiverine in urine after single administration. Pharmazie 1988;43:91-5
   PubMedGoogle Scholar
• Sugiyama Y, Yoshida M, Masunaga K, Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats. Int J Urol 2008;15:76-81
   PubMedGoogle Scholar
• Yamada S, Ito Y, Taki Y, The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. Drug Metab Dispos 2010;38:1314-21
   PubMed Web of Science ®Google Scholar
• Müller C, Siegmund W, Huupponen R, Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Eur J Drug Metab Pharmacokinet 1993;18:265-72
   PubMedGoogle Scholar
• Siegmund W, Sillén U, Läckgren G, Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder. Clin Pharmacokinet 2010;49:335-42
   PubMedGoogle Scholar
• May K, Giessmann T, Wegner D, Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. Eur J Clin Pharmacol 2008;64:1085-92
   PubMedGoogle Scholar
• Meisel P, Langner S, Siegmund W. In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. J Pharm Pharmacol 1997;49:270-2
   PubMedGoogle Scholar
• Haustein KO, Hüller G. On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet 1988;13:81-90
   PubMedGoogle Scholar
• Siepmann M, Nokhodian A, Thümmler D, Kirch W. Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol 1998;54:767-71
   PubMedGoogle Scholar
• Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005;33:1859-66
   PubMed Web of Science ®Google Scholar
• Siegmund W, Siegert J, Richter K, Influence of a Fat-Rich Meal on Bioavailability of Extended-Release and Immediate-Release Propiverine. J Clin Pharmacol 2012;52:681-90
   PubMedGoogle Scholar
• Kuipers ME, Krauwinkel WJ, Mulder H, Visser N. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D 2004;5:73-81
   PubMedGoogle Scholar
• Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet 2009;48:281-302
   PubMedGoogle Scholar
• Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001;2:1685-701
   PubMedGoogle Scholar
• Nilvebrant L, Andersson KE, Gillberg PG, Tolterodine–a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207
   PubMed Web of Science ®Google Scholar
• Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmcother 2000;11:13-27
   Google Scholar
• Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998;26:289-93
   PubMed Web of Science ®Google Scholar
• Brynne N, Stahl MM, Hallén B, Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997;35:287-95
   PubMed Web of Science ®Google Scholar
• Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-43
   PubMed Web of Science ®Google Scholar
• Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7
   PubMed Web of Science ®Google Scholar
• Ozawa S, Soyama A, Saeki M, Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004;19:83-95
   PubMedGoogle Scholar
• Brynne N, Dalén P, Alván G, Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998;63:529-39
   PubMed Web of Science ®Google Scholar
• Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001;40:227-35
   PubMed Web of Science ®Google Scholar
• Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001;18:277-304
   PubMed Web of Science ®Google Scholar
• Olsson B, Brynne N, Johansson C, Arnberg H. Food increases the bioavailability of tolterodine but not effective exposure. J Clin Pharmacol 2001;41:298-304
   PubMedGoogle Scholar
• Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia-chances for improvement of therapy. Int J Clin Pharmacol Ther 1999;37:209-18
   PubMed Web of Science ®Google Scholar
• Madersbacher H, Rovner E. Trospium chloride: the European Experience Expert Opin Pharmacother. 2006;7(10):1373-80, Indevus Pharmaceuticals, Inc., Sanctura™ (trospium chloride) prescribing information. Indevus Pharmaceuticals, Inc; Lexington, MA: 2004
   Google Scholar
• Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46
   PubMed Web of Science ®Google Scholar
• Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 1999;85:299-304
   PubMedGoogle Scholar
• Diefenbach K, Donath F, Maurer A, Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003;23:395-404
   PubMed Web of Science ®Google Scholar
• Madersbacher H, Rovner E. Trospium chloride: the European experience. Expert Opin Pharmacother 2006;7:1373-80
   PubMedGoogle Scholar
• Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733-54
   PubMed Web of Science ®Google Scholar
• MacDiarmid SA. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int 2007;99:8-12
   PubMedGoogle Scholar
• Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract 2010;64:1287-93
   PubMed Web of Science ®Google Scholar
• Krauwinkel WJ, Smulders RA, Mulder H, Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005;43:227-38
   PubMed Web of Science ®Google Scholar
• Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002;168:1027-31
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Abrams P, Marschall-Kehrel D, Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054-64
   PubMed Web of Science ®Google Scholar
• Herschorn S, Stothers L, Carlson K, Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 2010;183:1892-8
   PubMed Web of Science ®Google Scholar
• Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005;23:248-52
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, For The Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D, Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007;99:836-44
   PubMed Web of Science ®Google Scholar
• Burgio KL, Locher JL, Goode PS, Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000;95:718-21
   PubMed Web of Science ®Google Scholar
• MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005;174:1301-5
   PubMedGoogle Scholar
• Anderson RU, MacDiarmid S, Kell S, Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:502-11
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Nitti V, Staskin D, Luber K. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005;23:263-70
   PubMed Web of Science ®Google Scholar
• Gotoh M, Yokoyama O, Nishizawa O, Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol 2011;18:365-73
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Chapple C, Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006;13:692-8
   PubMed Web of Science ®Google Scholar
• Zinner NR, Dmochowski RR, Staskin DR, Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 2011;30:1214-19
   PubMedGoogle Scholar
• Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008;71:449-54
   PubMed Web of Science ®Google Scholar
• Rackley R, Weiss JP, Rovner ES, 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6
   PubMed Web of Science ®Google Scholar
• Herschorn S, Heesakkers J, Castro-Diaz D, Disease Management Study Team. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008;24:3513-21
   PubMed Web of Science ®Google Scholar
• Khullar V, Rovner ES, Dmochowski R, Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43
   PubMed Web of Science ®Google Scholar
• Vella M, Cardozo L. Review of fesoterodine. Expert Opin Drug Saf 2011;10:805-8
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Sand PK, Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
   PubMed Web of Science ®Google Scholar
• Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008;15(9):809-15
   PubMedGoogle Scholar
• Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008;15:986-91
   PubMedGoogle Scholar
• Homma Y, Yamaguchi O. Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16:499-506
   PubMed Web of Science ®Google Scholar
• Zaitsu M, Mikami K, Ishida N. Takeuchi T. comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group Trial (the LIST Study). Adv Urol 2011;2011:854697
   PubMedGoogle Scholar
• Vesicare® (Solifenacin succinate). Full prescribing information. Yamanouchi Pharma America, Inc. And GlaxoSmithKline; Norman, Ok, USA: 2004
   Google Scholar
• Cardozo L, Lisec M, Millard R, Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24
   PubMed Web of Science ®Google Scholar
• Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580-6
   PubMed Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;CD003781
   Google Scholar
• Madhuvrata P, Cody JD, Ellis G, Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
   PubMedGoogle Scholar
• Harrington AM, Peck CJ, Liu L, Localization of muscarinic receptors M1R, M2R and M3R in the human colon. Neurogastroenterol Motil 2010;22:999-1008
   PubMed Web of Science ®Google Scholar
• Meek PD, Evang SD, Tadrous M, Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011;56:7-18
   PubMed Web of Science ®Google Scholar
• Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471-7
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Schneider T, Foote JE, Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2011;107:1432-40
   PubMed Web of Science ®Google Scholar
• Cardozo L, Hessdörfer E, Milani R, SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
   PubMed Web of Science ®Google Scholar
• Zinner NR, Dmochowski RR, Staskin DR, Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 2011;30:1214-19
   PubMedGoogle Scholar
• Chapple CR, Khullar V, Gabriel Z, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Ishizaka N, Noda M, Yokoyama S, Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 1998;787:344-7
   PubMed Web of Science ®Google Scholar
• Cardozo L, Hessdörfer E, Milani R, SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95
   PubMed Web of Science ®Google Scholar
• Höfner K, Oelke M, Machtens S, Grünewald V. Trospium chloride–an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19:336-43
   PubMed Web of Science ®Google Scholar
• Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011;72:186-96
   PubMed Web of Science ®Google Scholar
• Olshansky B, Ebinger U, Brum J, Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther 2008;13:241-51
   PubMed Web of Science ®Google Scholar
• Malhotra B, Wood N, Sachse R, Gandelman K. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010;48:309-18
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Chapple C, 1032 Study Group. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006;13:692-8
   PubMed Web of Science ®Google Scholar
• Michel MC,Wetterauer U, Vogel M, De la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008;31:505-14
   PubMed Web of Science ®Google Scholar
• Pfizer Detrol® (tolterodine tartrate tablets) US prescribing information March, 2008. Available from: http://media.pfizer.com/files/products/uspi_detrol.pdf [Last accessed 14 August 2010]
   Google Scholar
• Breuel HP, Mürtz G, Bondy S, Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993;43:461-4
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Drici MD, Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85
   PubMed Web of Science ®Google Scholar
• Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol 2007;39:1069-77
   PubMedGoogle Scholar
• Serra DB, Affrime MB, Bedigian MP, QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
   PubMed Web of Science ®Google Scholar
• Malhotra BK, Glue P, Sweeney K, Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
   PubMed Web of Science ®Google Scholar
• Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996;41:73-5
   PubMed Web of Science ®Google Scholar
• Guay DR. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag 2005;1:157-67
   PubMedGoogle Scholar
• Dorschner W, Stolzenburg JU, Griebenow R, Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US VESIcare® (solifenacin succinate) US prescribing information. 2010. Available from: http://www.astellas.us/docs/vesicare.pdf [Last accessed 7 July 2012]
   Google Scholar
• Asajima H, Sekiguchi Y, Matsushima S, QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 2008;66:896-7
   PubMed Web of Science ®Google Scholar
• Serra DB, Affrime MB, Bedigian MP, QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
   PubMed Web of Science ®Google Scholar
• Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther 2011;49:353-65
   PubMed Web of Science ®Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 2012;18:167-74
   PubMed Web of Science ®Google Scholar
• Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011;59:1332-9
   PubMed Web of Science ®Google Scholar
• Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011;12:351-7
   PubMedGoogle Scholar
• Swinburn P, Lloyd A, Ali S, Preferences for antimuscarinic therapy for overactive bladder. BJU Int 2011;108:868-73
   PubMed Web of Science ®Google Scholar
• Kraus SR, Ruiz-Cerdá JL, Martire D, Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010;76:1350-7
   PubMed Web of Science ®Google Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
   PubMedGoogle Scholar
• Staskin D, Khullar V, Michel MC, Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 2011;30:1480-5
   PubMed Web of Science ®Google Scholar
• Sand PK, Goldberg RP, Dmochowski RR, The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006;195:1730-5
   PubMed Web of Science ®Google Scholar
• Serati M, Salvatore S, Uccella S, Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. Eur Urol 2008;54:911-15
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809-12
   PubMed Web of Science ®Google Scholar
• Stöhrer M, Mürtz G, Kramer G, Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity–results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51:235-42
   PubMedGoogle Scholar
• Barkin J, Corcos J, Radomski S, UROMAX Study Group. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004;26:1026-36
   PubMed Web of Science ®Google Scholar
• Study report 137-219. Double blind, placebo controlled, four- way crossover study to investigate the toleration, safety, pharmacokinetics and pharmacodynamics of single escalating doses of intravenous darifenacin in healthy male volunteers. Novartis; East Hanover (NJ): 2001; Data on file
   Google Scholar
• Zobrist RH, Quan D, Thomas HM, Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003;20:103-9
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK, Sand PK, Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig 2011;31(8):559-71
   PubMed Web of Science ®Google Scholar
• May K, Westphal K, Giessmann T, Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms. J Clin Pharmacol 2008;48:570-9
   PubMedGoogle Scholar
• Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004;44(9):1023-33
   PubMed Web of Science ®Google Scholar
• Silver N, Sandage B, Sabounjian L, Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol 2010;50:143-50
   PubMedGoogle Scholar